Drug Discovery in Oncology

The conventional paradigm of demanding proof of an anti-cancer drug's potency by demonstrating tumour shrinkage using conventional anatomical imaging is not consistent with the newer therapeutics, especially the chemostatic agents where the size of the tumour does not necessarily decrease in successful treatment. The use of proliferation marker agents such as 18F labelled fluorothymidine (FLT) and PET may show an earlier response [9]. Pharmaceutical companies now have the option of using radiolabelled proliferation agents in Phase I or Phase II to choose which compounds to advance to the next phase.

Was this article helpful?

0 0

Post a comment